Multitargeted approaches to symptom relief and novel disease-targeting interventions are improving the clinical management of chronic obstructive pulmonary disorder (COPD). Recently approved fixed-triple therapy in a single inhaler reduces treatment burden, improves therapy compliance and symptom relief. Inhibiting pro-inflammatory eosinophils, valve surgery and airway tissue regeneration are currently being explored. Patient-focussed pulmonary rehabilitation strategies are offering a more holistic approach to care, improving well-being and quality of life for patients living with COPD.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Henrik Hansen, ERS 2019 – Pulmonary Tele-rehabilitation Versus Conventional Rehabilitation (Part 1)
We met Henrik Hansen, from National University Hospital, Copenhagen, Denmark, at ERS 2019 to discuss his study results – 1-year follow-up of pulmonary tele-rehabilitation versus conventional pulmonary rehabilitation. Questions 1. What are the limitations of current pulmonary rehabilitation programmes? (0:05) 2. What are the potential advantages and limitations of tele-rehabilitation? (1:44) Speaker disclosures: Henrik Hansen […]
Henrik Hansen, ERS 2019 – Pulmonary Tele-rehabilitation Versus Conventional Rehabilitation (Part 2)
We met Henrik Hansen, from National University Hospital, Copenhagen, Denmark, at ERS 2019 to discuss his study results – 1-year follow-up of pulmonary tele-rehabilitation versus conventional pulmonary rehabilitation. Questions 1. Could you tell us a little about your recent clinical trial investigating tele-rehabilitation? (0:05) 2. Which patients are most likely to benefit from this approach? […]
Gerard Criner, ERS 2019 – Identification of Patients with COPD who Benefit from Benralizumab
We met with Gerard Criner, of Temple University, at ERS 2019 in Madrid, to discuss his presentation on identification of patients with chronic obstructive pulmonary disease who benefit from benralizumab. Questions 1. What is the mechanism of action of benralizumab? 2. Could you tell us a little about the aims and design of the GALATHEA […]
Peter J Barnes, ERS 2019 – COPD as a Disease of Accelerated Lung Ageing
It was delightful to speak to Editorial Board member Peter J Barnes at ERS 2019 in Madrid about chronic obstructive pulmonary disease as a disease of accelerated lung ageing. Questions 1. What are the main similarities between ageing lungs and the lungs of chronic obstructive pulmonary disease (COPD) patients? (0:07) 2. What have these similarities […]
Kirsten Almberg – Black lung, lung cancer, COPD in US coal miners
At the American Thoracic Society meeting, Dr Kirsten Almberg discussed the rise of black lung, lung cancer, and chronic obstructive pulmonary disease (COPD) in US coal miners. Here, she reiterates the results of two studies assessing mortality in US-based coal miners and the further work that needs to be done to better understand the health […]
Hiroki Tateno – Novel CureApp for smoking cessation
At the American Thoracic Society meeting, Dr Hiroki Tateno shared the results of a randomized, sham-controlled, open-label study to evaluate the long-term efficacy of CureApp, a novel smoking cessation app (CureApp Inc.), when used in addition to pharmacotherapy. Questions 1. What smoking cessation aids are currently available and how successful have they been in achieving […]
Nirupama Putcha and Elizabeth Oelsner, ATS 2019 – Asthma COPD Overlap, NHLBI Pooled Cohorts Study
Nirupama Putcha (Johns Hopkins University, Baltimore, MD, USA) and Elizabeth Oelsner (Columbia University Medical Center, New York, NY, USA) speak from the 2019 ATS conference in Dallas, TX, USA about their study into patients with asthma–chronic obstructive pulmonary disease (COPD) overlap (ACO) and its prognostic impact compared with asthma and COPD; the implications of their […]
Nick Hanania, ATS 2019 – The Role of ICs in COPD
At the 2019 ATS conference in Dallas, TX, USA, Nick Hanania (Baylor College of Medicine, Houston, TX, USA), discusses unmet needs in the management of patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) at risk of exacerbations; the budesonide/formoterol fumarate metered dose inhaler (BFF MDI) and how it differs from other COPD inhaled corticosteroid/bronchodilator combination; […]
Don Sin, ATS 2019 – COPD – A Disease of Accelerated Aging
Don Sin (University of British Columbia, Vancouver, Canada; St Paul’s Hospital, Vancouver, Canada) speaks from the 2019 ATS conference in Dallas, TX, USA about the indicators that COPD is a disease of accelerated aging and the impacts of accelerated aging on patients. He also discusses the further work needs to be performed to understand COPD […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!